Secukinumab therapy proved safe and effective for psoriatic arthritis patients with multiple co-morbidities and long treatment histories, according to recent research…
RA Patients May Safely Stop Methotrexate in Tofacitinib Combination Therapy
RA patients who achieve low disease activity on tofacitinib and methotrexate combination therapy can safely cease methotrexate use, according to recent research…
Subcutaneous CT-P13 Injection Evaluated for Safety & Efficacy of in RA Patients
Results from a one-year study suggest subcutaneous CT-P13, which is biosimilar to infliximab, is as safe and effective for RA patients as intravenous (IV) CT-P13 and IV infliximab…
Upadacitinib + Methotrexate & Other csDMARDs in RA Patients
A post-hoc analysis showed upadacitinib is safe and effective for treating RA patients when used with methotrexate or non-methotrexate csDMARDs…
Ankylosing Spondylitis Patients Report Improved Quality of Life with Bimekizumab
Recent research shows bimekizumab may improve patient-reported outcomes and quality of life for ankylosing spondylitis (AS) patients…
Ixekizumab vs. Adalimumab for PsA: How Do They Compare?
In a study of bDMARD-naive patients with active PsA and skin disease, ixekizumab proved more efficacious than adalimumab…
ARP Collaborates with EULAR’s Health Professionals in Rheumatology
The Association of Rheumatology Professionals (ARP) and European League Against Rheumatism Health Professionals in Rheumatology (EULAR HPR) are, to a great extent, working toward addressing the same long-term goals and challenges. Despite differences in healthcare services, culture, organization and economical aspects across the Atlantic Ocean, we can help each other overcome these challenges and learn…
Delayed Care: Research Paints Complex Picture of Treatment Delays
AMSTERDAM—A variety of factors lead to delays in patients seeking medical care for rheumatoid arthritis—from the nature of symptoms to coping tendencies—requiring more awareness from physicians when managing patients, researchers said at EULAR: the Annual European Congress of Rheumatology. Longer delays in treatment bring about more emotional distress to patients, missed chances to ease symptoms…
Promising Avenues in Myositis: Research Targets Disease Specificity
AMSTERDAM—Research in myositis treatments is beginning to find its way, with investigators pursuing avenues special to the disease so therapy for patients may no longer involve piggybacking on existing treatments for other illnesses, an expert said at EULAR: the Annual European Congress of Rheumatology. “Finally, in myositis there are targets being investigated that are more…
Investigators Assess Infection Risk with RA Biologics
Due to a range of factors, determining the precise infection risk posed by new biologic therapies to RA patients is difficult. But progress has been made and health registries may be helpful, said Olivier Lortholary, MD, PhD, during the 2018 EULAR: Annual European Congress of Rheumatology…
- « Previous Page
- 1
- …
- 5
- 6
- 7
- 8
- 9
- …
- 13
- Next Page »